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ABSTRACT
Introduction: Infections due to Klebsiella pneu-
moniae carbapenemase (KPC)-producing Enter-
obacteriaceae are associated with increased
morbidity and high mortality.
Meropenem–vaborbactam (MV) is a novel b-
lactam/b-lactamase inhibitor combination
active against KPC-producing Enterobacteriaceae.
The aim of this post hoc analysis of the TANGO-
II randomized controlled trial was to assess the
efficacy of MV versus best available therapy
(BAT) in the subgroup of patients without prior
antimicrobial failure.
Methods: The primary outcome measure was
clinical cure at the test of cure (TOC). Secondary
outcome measures included (1) clinical cure at
the end of therapy (EOT), (2) microbiological
cure at TOC, (3) microbiological cure at EOT,
and (4) 28-day all-cause mortality.
Results: First-line MV was associated with a
42.9% absolute increase in clinical cure rate at
TOC (95% confidence intervals [CI] 13.7–72.1)
in comparison with first-line BAT. A 49.3%
absolute increase in clinical cure rate at EOT
(95% CI 20.8–77.7), a 42.6% absolute increase
in microbiological cure rate at EOT (95% CI
13.4–71.8), and a 36.2% absolute increase in
microbiologic cure rate at TOC (95% CI
5.9–66.6) were also observed, in addition to a
29.0% absolute reduction in mortality (95% CI
- 54.3 to - 3.7). Overall, fewer adverse events
were observed in the MV group than in the BAT
group.
Conclusion: MV was superior to BAT in the
subgroup of patients with serious carbapenem-
resistant Enterobacteriaceae (CRE) infections and
no prior antimicrobial failure, with very high
rates of clinical success, and was well tolerated.
Post approval and real-world studies remain
essential to clearly define the most appropriate
population for early, empirical MV coverage, in
accordance with antimicrobial stewardship
principles.
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Antimicrobial resistance is increasing world-
wide, and serious infections due to carbapenem-
resistant Enterobacteriaceae (CRE) have been
associated with increased morbidity and high
mortality [1–8]. In the last decade, the treat-
ment of serious CRE infections was frequently
based on the combination of last-resort agents
associated with nephrotoxicity, possible sub-
therapeutic concentrations, and/or intermedi-
ate in vitro activity due to limited options and
resistance to several classes of antimicrobials
[1–3, 9].
Meropenem–vaborbactam (MV) is the com-
bination of a well-known carbapenem with a
first-in-class, boron-based, b-lactamase inhi-
bitor, able to inhibit Klebsiella pneumoniae car-
bapenemase (KPC), which is one of the most
frequent carbapenemases responsible for CRE
[10]. MV has been approved by the US Food and
Drug Administration (FDA) for the treatment of
complicated urinary tract infections (cUTI),
including pyelonephritis, based on the TANGO-
I randomized controlled trial (RCT), comparing
efficacy and safety of MV to piperacillin–ta-
zobactam [11]. Furthermore, MV has also been
recently approved by the European Medicines
Agency (EMA) for cUTI and pyelonephritis,
complicated intra-abdominal infections (cIAI),
hospital-acquired pneumonia (HAP), ventilator-
associated pneumonia (VAP), and infections
due to aerobic Gram-negative organisms in
adult patients with limited treatment options.
Results of the TANGO-II RCT, in which MV
monotherapy was compared with best available
therapy (BAT) for the treatment of adults with
serious infections due to CRE, have also been
recently published [12]. In TANGO-II, MV was
associated with increased clinical cure and
decreased mortality in comparison with BAT,
and less nephrotoxicity [12]. However, patients
with prior antimicrobial failure (PAF), who are
expected to have a lower response also to
salvage therapy, were enrolled only in the MV
arm [12]. Therefore, the advantage of MV over
BAT could be expected to be even higher than
observed in the TANGO-II RCT when both MV
and BAT are employed as first-line therapies.
The aim of this post hoc analysis of the
TANGO-II RCT was to assess the efficacy of MV
versus BAT in the subgroup of patients without
prior antimicrobial failure.
METHODS
This was a post hoc analysis of a phase 3, mul-
ticenter, multinational, randomized, open-la-
bel, active-controlled study comparing MV
monotherapy to BAT for the treatment of seri-
ous infections suspected or known to be caused
by CRE in patients aged 18 years or older, from
November 2014 to June 2017 (NCT02168946)
[12]. Serious CRE infections included cUTI and
acute pyelonephritis (AP), hospital-acquired/
ventilator-associated bacterial pneumonia
(HABP/VABP), bacteremia, or cIAI [12].
Only patients without PAF and belonging to
the microbiologic-CRE-modified intent-to-treat
(mCRE-MITT) population were included in this
analysis and were divided in two groups: (1)
patients who received MV monotherapy as first-
line therapy; (2) patients who received BAT as
first-line therapy. The primary outcome mea-
sure was clinical cure at the test of cure (TOC).
Secondary outcome measures included (1)
clinical cure at the end of therapy (EOT), (2)
microbiological cure at TOC, (3) microbiologi-
cal cure at EOT, and (4) 28-day all-cause
mortality.
The protocol of the TANGO-II trial and the
informed consent form were approved by the
sites’ institutional review boards/independent
ethics committees. All procedures were in
accordance with the ethical standards of the
institutional and/or national research commit-
tee and with the 1964 Helsinki declaration and
its later amendments or comparable ethical
standards. Informed consent was obtained from
all individual participants included in the study
or from their guardian/legal representative.
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Population and Definitions
The mCRE-MITT population was defined as
patients receiving at least one dose of study
drug and with a baseline isolate confirmed as
CRE by local or central laboratories. The safety
population consisted of patients receiving at
least one dose of study drug. BAT was defined as
an antibiotic therapy including any of the fol-
lowing, alone or in combination: carbapenems,
aminoglycosides, polymyxin B, colistin, tigecy-
cline, or monotherapy ceftazidime–avibactam.
Prior antimicrobial failure was defined as clini-
cal evidence of prior failure as ascertained by
the study investigator at screening and ran-
domization. Clinical cure was defined as com-
plete resolution of symptoms of the index
infection such that no further antimicrobial
therapy (and/or surgical intervention for cIAI)
was required. Microbiologic cure was defined as
microbial eradication or presumed eradication
(i.e., clinical cure in absence of culture samples
collected at the respective visit [EOT or TOC]).
Outcomes at TOC were assessed at 7 ± 2 days
after EOT.
Intervention
Meropenem–vaborbactam monotherapy (2 g/
2 g) was administered for 7–14 days as a 3-h
intravenous infusion every 8 h. BAT was selec-
ted according to institutional standards of care
[12]. Detailed information on treatments
received by BAT patients are available in the
supplementary material of the original TANGO-
II publication [12].
Statistical Analysis
Descriptive demographic and clinical charac-
teristics of patients are reported with number
and percentages for categorical variables, and
with mean and standard deviation (SD) for
continuous variables. Absolute percentage dif-
ferences in primary and secondary outcome
measures between subgroups are presented with
their 95% confidence intervals (CI) [12].
RESULTS
Demographic and clinical characteristics of
patients are reported in Table 1. There was a
high proportion of patients with systemic
inflammatory response syndrome (17/38,
44.7%) and/or immunocompromised status
(15/38, 39.5%).
As shown in Table 2, first-line MV was asso-
ciated with a 42.9% absolute increase in clinical
cure rate at TOC (95% CI 13.7–72.1) in com-
parison with first-line BAT. A 49.3% absolute
increase in clinical cure rate at EOT (95% CI
20.8–77.7), a 42.6% absolute increase in micro-
biological cure rate at EOT (95% CI 13.4–71.8),
and a 36.2% absolute increase in microbiologic
cure rate at TOC (95% CI 5.9–66.6) were also
observed, in addition to a 29.0% absolute
reduction in mortality (95% CI - 54.3 to - 3.7).
Overall, fewer adverse events were observed in
the MV group than in the BAT group (Table S1).
Additional comparisons between MV-treated
patients with and without prior antimicrobial
failure are available as supplementary material
(Tables S2, S3). No comparison was made
between MV-treated patients with PAF and
patients treated with first-line BAT because of
the small subgroups.
DISCUSSION
In patients without PAF, MV showed increased
efficacy (clinical cure at TOC) and reduced
28-day all-cause mortality compared to BAT
(? 42.9% and - 29.0%); these changes were
greater than those observed in the original
TANGO-II RCT (? 32.7% and - 17.7%), in
which the MV group included patients with
prior antimicrobial failure [12].
As a result of the small sample size, definitive
conclusions could not be drawn (connected to
the early study termination of the TANGO-II
RCT due to superiority of MV at an interim
analysis); however, these results, in comparison
with those of the original trial, are suggestive of
an additional advantage of MV over BAT when
both are administered as a first-line therapy.
This raises an important point of discussion,
that is the need for a correct balance between
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Age, mean (SD) 62.3 (14.6) 60.2 (13.0) 61.5 (13.9)
Female gender 12 (52.2) 5 (33.3) 17 (44.7)
White race 19 (82.6) 12 (80.0) 31 (81.6)
Region
North America 6 (26.1) 7 (46.7) 13 (34.2)
Europe 11 (47.8) 8 (53.3) 19 (50.0)
Israel, Colombia, Brazil,
Argentina
6 (26.1) 0 (0) 6 (15.8)
BMI, mean (SD) 27.0 (7.7) 25.8 (7.6) 26.5 (7.6)
Infection type
Bacteremia 10 (43.5) 8 (53.3) 18 (47.4)
cUTI/AP 9 (39.1) 4 (26.7) 13 (34.2)
HABP/VABP 3 (13.0) 1 (6.7) 4 (10.5)
cIAI 1 (4.3) 2 (13.3) 3 (7.9)
Baseline pathogena
Klebsiella pneumoniae 22 (95.7) 12 (80.0) 34 (89.5)
Escherichia coli 2 (8.7) 1 (6.7) 3 (7.9)
Enterobacter cloacae species
complex
0 (0) 2 (13.3) 2 (5.3)
Proteus mirabilis 0 (0) 2 (13.3) 2 (5.3)
Serratia marcescens 1 (4.3) 1 (6.7) 2 (5.3)
Creatinine clearance (mL/min)
C 50 17 (73.9) 9 (60.0) 26 (68.4)
30–49 3 (13.0) 2 (13.3) 5 (13.2)
20–29 1 (4.3) 2 (13.3) 3 (7.9)
\ 20 1 (4.3) 0 (0) 1 (2.6)
Missing 1 (4.3) 2 (13.3) 3 (7.9)
Charlson comorbidity index
B 2 3 (13.0) 1 (6.7) 4 (10.5)
3–4 2 (8.7) 2 (13.3) 4 (10.5)
5 6 (26.1) 1 (6.7) 7 (18.4)
C 6 12 (52.2) 11 (73.3) 23 (60.5)
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limiting the use of novel agents to delay emer-
gence of further resistance and, at the same
time, guaranteeing the most active early ther-
apy in case of severe infection. This is particu-
larly important for CRE, by considering
together the following reasons: (1) CRE infec-
tions are endemic in several countries [8], (2)
there is a frequent delay of active therapy in
patients with CRE infections [8], and (3) there is
lower survival of patients with severe infections
when active therapy is delayed [1].
Innovative, pathogen-focused trials enrol-
ling vulnerable patients are essential to under-
standing the efficacy and safety of novel agents
in real target populations. This is also important
when a reference therapy standard is not
established and multidrug-resistant (MDR)








Diabetes mellitus 8 (34.8) 7 (46.7) 15 (39.5)
SIRS 11 (47.8) 6 (40.0) 17 (44.7)
ICU admission 3 (13.0) 3 (20.0) 6 (15.8)
Immunocompromisedb 7 (30.4) 8 (53.3) 15 (39.5)
Results are reported as n (%) unless otherwise indicated
AP acute pyelonephritis, BMI body mass index, cIAI complicated intra-abdominal infection, cUTI complicated urinary tract
infection, HABP hospital-acquired bacterial pneumonia, ICU intensive care unit, VABP ventilator-associated bacterial
pneumonia, PAF prior antimicrobial failure, SD standard deviation, SIRS systemic inflammatory response syndrome
a Only baseline pathogens occurring in 2 or more subjects are shown
b Defined as receipt of immunosuppressive medications or bone marrow ablative chemotherapy, underlying lymphoma or
leukemia (not in remission), previous transplantation, splenectomy, or presence of neutropenia









Clinical cure at TOC 16 (69.6) 4 (26.7) ? 42.9 (? 13.7 to
? 72.1)
Clinical cure at EOT 19 (82.6) 5 (33.3) ? 49.3 (? 20.8 to
? 77.7)
Microbiologic curea at EOT 19 (82.6) 6 (40.0) ? 42.6 (? 13.4 to
? 71.8)
Microbiologic curea at TOC 16 (69.6) 5 (33.3) ? 36.2 (? 5.9 to
? 66.6)
Day 28 mortality 1 (4.3) 5 (33.3) - 29.0 (- 54.3 to
- 3.7)
CI confidence intervals, EOT end of therapy, mCRE-MITT microbiologic carbapenem-resistant Enterobacteriaceae modified
intent-to-treat, TOC test of cure
a Microbiologic cure was defined as microbial eradication or presumed eradication
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trial, since difficult-to-treat vulnerable popula-
tions could be exposed to less effective and
more toxic agents because of the paucity of
active options. The TANGO-II trial included
both immunocompromised patients and
patients with prior antimicrobial failure, who
are usually excluded from RCTs [12]. In addi-
tion, there still is the need for updated knowl-
edge of the local, molecular, microbiological
epidemiology as well as the patients’ medical
history (e.g., colonization, previous infections
and antibiotic therapies, travel in countries or
regions endemic for KPC-producing CRE) to
make informed treatment decisions.
This post hoc analysis has some limitations.
The most important is that this is a subgroup
analysis of small sample size which prevents
definitive conclusions, as well as further sub-
grouping (e.g., according to continent/country
of enrollment, causative organism, baseline
characteristics). However, it is noteworthy that
the independent data safety monitoring board
recommended to stop randomization to BAT
because the risk/benefit analysis did not support
further BAT randomization at an interim anal-
ysis [12], which, together with the present post
hoc analysis, supports the suggestion of a
potential advantage of MV as first-line therapy,
to be explored further in post-approval studies.
Another limitation is the heterogeneity in BAT,
which is nonetheless consistent with the real-
life approach to KPC-producing CRE infections
at the time of the study, when there was not a
unique standard reference.
CONCLUSIONS
MV was superior to BAT in the subgroup of
patients with serious CRE infections and no
PAF, with very high rates of clinical success, and
was well tolerated. Post approval and real-world
studies remain essential to clearly define the
most appropriate population for early, empiri-
cal MV coverage, in accordance with antimi-
crobial stewardship principles.
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